Over the past few decades, replication-defective recombinant adenovirus has become a widely used model system in areas such as eukaryotic gene expression analysis, vaccine research, and gene therapy. In this article, we will briefly describe genetically recombinant lysosomal adenovirus.
Oncolytic adenoviruses are a class of natural or genetically modified viruses that can selectively infect and kill tumor cells with little damage to normal cells. For patients with unresectable or postoperative recurrent metastatic nasopharyngeal cancer, the initial treatment may be H101 intratumoral injection combined with cisplatin and 5-fluorouracil (5-FU). For HCC patients with unresectable, Child-Pugh liver function grade A or B, and no extrahepatic metastasis, initial treatment may consider hepatic artery injection of H101 combined with transarterial chemoembolization (TACE).
Lysoviruses may have synergistic anti-tumor benefits in combination with chemotherapy, radiotherapy, targeted therapy, or immunotherapy. In malignant tumors, especially in patients with refractory tumors, there is a greater potential for registry clinical studies to expand the therapeutic modalities of lysosomal viruses. The combination of different therapies, the selection criteria for applicable patients, the dosage administered, the order of administration, and the time interval may affect the antitumor activity of lysoma viruses.
Liver metastatic cancer: Preclinical studies and early clinical trials have confirmed the favorable safety profile of lysovirus therapy in patients with liver metastases from colorectal cancer and have demonstrated preliminary antitumor activity. Further clinical studies are recommended to expand the indications for lysovirus in patients with liver metastatic cancer.
Glioma: The safety of lysoviral therapy for malignant gliomas has been confirmed in numerous preclinical and early clinical trials. Registry studies are recommended to further validate the anti-tumor efficacy of lysoviral therapy in patients with malignant glioma.
Pancreatic cancer: Lysoviral therapy has a favorable safety and efficacy profile in patients with pancreatic cancer. Large-sample, high-quality clinical studies are recommended to expand the indications for lysosomal viruses in patients with pancreatic cancer.
With the successive approval of recombinant adenovirus and the discovery of combination therapies, it is playing an increasingly prominent role in tumor treatment and is expected to become a breakthrough immunotherapy. In the future, in addition to conducting more high-quality clinical trials to further expand the indications for recombinant adenovirus, we should continue to develop more effective drugs and explore its combination strategy with other drugs to improve the treatment regimen.
Hanbio is a high-tech enterprise focused on recombinant adenovirus and adenovirus packaging. Hanbio has always been committed to the research and production of gene vectors, and our core competitive products include lentiviral vector construction, adenoviruses, and adeno-associated viruses.
